Hôpital Universitaire Sahloul Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2018
NCT03724448
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CHU Sahloul, Sousse, Tunisia | Hôpital Universitaire Sahloul | HU Sahloul

Active Ingredients

Drugs in Phase 1 Trials (4)

aleozen (1 trial)

multivitamins (1 trial)

nigella sativa (2 trials)

quercetin (2 trials)

Drugs in Other Trials (1)

colloidal silver (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mental Disorders (Phase 1)

Stress Disorders, Post-Traumatic (Phase 1)

Stress Disorders, Traumatic (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 7
  • # of Trial APIs: 5